Galapagos « Terug naar discussie overzicht

quote:

Glycostem tech schreef op 2 augustus 2015 18:22:

As midsize investor we are careful with GLPG and sold a large position end of last week. We all know the Pfizer story regarding Xeljanz (tofacitinib) - which is comparable to filgotinib as a JAK- inhibitor. Although, now approved by the FDA for the US market - European approval was turned down due to overall safety concerns and serious side effects. So far, in Darwin studies there are less than 600 patients only (including low dose and placebo groups) and already one death in the verum group due to pneumonia ! Approval for tofacitinib was denied in the EU after records of 3300 patient files were submitted - and benefits of this drug did not outweigh the risks (immunosuppression, liver damage, cancer and gastro-intestinal perforations). Pfizer shares dropped 3% after the announcement of 4 tofacitinib related death in 2011. Galapagos market value heavily depends (at least at the moment) on this single drug - all others are still too far from market.
One should think about it.

quote:

Glycostem tech schreef op 2 augustus 2015 18:22:

As midsize investor we are careful with GLPG and sold a large position end of last week. We all know the Pfizer story regarding Xeljanz (tofacitinib) - which is comparable to filgotinib as a JAK- inhibitor. Although, now approved by the FDA for the US market - European approval was turned down due to overall safety concerns and serious side effects. So far, in Darwin studies there are less than 600 patients only (including low dose and placebo groups) and already one death in the verum group due to pneumonia ! Approval for tofacitinib was denied in the EU after records of 3300 patient files were submitted - and benefits of this drug did not outweigh the risks (immunosuppression, liver damage, cancer and gastro-intestinal perforations). Pfizer shares dropped 3% after the announcement of 4 tofacitinib related death in 2011. Galapagos market value heavily depends (at least at the moment) on this single drug - all others are still too far from market.
One should think about it.

quote:

djyves schreef op 2 augustus 2015 12:06:

Verwachtingen voor Maandag 10 Augustus slotkoers (in Euro):
Grapesharvester 70
Springinhetveld 65,49
MtBaker 63.47
Wonderwoman 62,22
SJURMV 61,00
Gorden Gekko 60,05
Hee jij ook hier 58.25
Mooiweer 57.50
Alan B'stard 52-56+
Ruud Rubbers 59,00
mickjagger2 € 61,25
biffy € 56,43
djvyes € 55,00

quote:

mr. gala schreef op 2 augustus 2015 20:58:

[...]

Nagenoeg al deze mensen gaan morgen bestens bijkopen bij opening? Is toch een mooi rendement in ruim een week....

quote:

MtBaker schreef op 2 augustus 2015 22:20:

Verwachtingen voor Maandag 10 Augustus slotkoers (in Euro):
Grapesharvester 70
Springinhetveld 65,49
MtBaker 63.47
Wonderwoman 62,22
mickjagger2 € 61,25
SJURMV 61,00
Gorden Gekko 60,05
Ruud rubbers 59
Bogo 58,55
Hee jij ook hier 58.25
Mooiweer 57.50
Biffy 56.43
Grrrrr PFFFFF zucht 56.2
Twinkletown 54,50 en 55,50
Cees01 53.85
Djyves 53 en 55
Alan B'stard 52-56+

quote:

MtBaker schreef op 2 augustus 2015 22:20:

Verwachtingen voor Maandag 10 Augustus slotkoers (in Euro):
Grapesharvester 70
Springinhetveld 65,49
MtBaker 63.47
Wonderwoman 62,22
mickjagger2 € 61,25
SJURMV 61,00
Gorden Gekko 60,05
Ruud rubbers 59
Bogo 58,55
Hee jij ook hier 58.25
Mooiweer 57.50
Biffy 56.43
Grrrrr PFFFFF zucht 56.2
Twinkletown 54,50 en 55,50
Djyves 53 en 55
Alan B'stard 52-56+

quote:

Glycostem tech schreef op 2 augustus 2015 18:22:

As midsize investor we are careful with GLPG and sold a large position end of last week. We all know the Pfizer story regarding Xeljanz (tofacitinib) - which is comparable to filgotinib as a JAK- inhibitor. Although, now approved by the FDA for the US market - European approval was turned down due to overall safety concerns and serious side effects. So far, in Darwin studies there are less than 600 patients only (including low dose and placebo groups) and already one death in the verum group due to pneumonia ! Approval for tofacitinib was denied in the EU after records of 3300 patient files were submitted - and benefits of this drug did not outweigh the risks (immunosuppression, liver damage, cancer and gastro-intestinal perforations). Pfizer shares dropped 3% after the announcement of 4 tofacitinib related death in 2011. Galapagos market value heavily depends (at least at the moment) on this single drug - all others are still too far from market.
One should think about it.

quote:

Investor68 schreef op 3 augustus 2015 00:25:

[...vAs far as we know to this date, Filgotinib does not have any of the risks that you associated with tofacitinib such as "immunosuppression, liver damage, cancer and gastro-intestinal perforations." Therefore, your comment is actually misleading. You should not compare Filgotinib to Tofacitinib in the manner in which you did it. It is very unprofessional, given that you call yourself a "midsize investor." I suggest that you should do a better and more objective research on filgotinib. Galapagos has a lot of potential. If we take into account the major products in Galapagos' pipeline, I think that most fair-minded people would agree that Galapagos' current share price (60,65 dollars) is significantly undervalued. If Galapagos were to be an American company, with all the fantastic results the company has produced so far, it would have been trading at somewhere between 100 to 150 dollars by now. It seems as if European pharmaceutical companies tend to get lower valuations than their American counterparts and this is not fair. This practise must be corrected!

quote:

mr. gala schreef op 3 augustus 2015 09:14:

Nog meer problemen met inloggen bij binck?